Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add filters








Language
Year range
2.
Radiol. bras ; 52(3): 166-171, May-June 2019. tab, graf
Article in English | LILACS-Express | LILACS | ID: biblio-1012931

ABSTRACT

Abstract Objective: To evaluate the imaging findings of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) and computed tomography (CT) in patients with additional primary tumors, correlating the results with those of the method used in order to elucidate the diagnosis and of the pathology reports. Materials and Methods: We retrospectively analyzed the medical records, pathology reports and images of 11 patients who underwent CT, 18F-FDG PET/CT, or both. We included patients with at least two tumors, with confirmed distinct histopathological profiles, at different sites. Patients in whom there was no diagnostic confirmation were excluded, as were those in whom the additional lesion was suspected of being a metastasis of the first. Results: New primary malignancies were identified in 11 patients, one new tumor being found in 10 and two new tumors being found in 1. The confirmed sites of the additional malignancies were the lung, kidney, prostate, jejunum, and breast. Single or multiple percutaneous biopsies were performed in 10 patients, and 1 patient underwent a surgical procedure for diagnostic and therapeutic purposes. The tumors were metachronous in 6 cases and synchronous in 5. Conclusion: CT and 18F-FDG PET-CT combined with multiple percutaneous biopsy could facilitate the diagnosis of additional lesions, thus optimizing the treatment and follow-up of the affected patients.


Resumo Objetivo: Avaliar os achados de imagem da tomografia computadorizada por emissão de pósitrons com 18F-fluordesoxiglicose (18F-FDG PET/TC) e tomografia computadorizada (TC) em pacientes portadores de tumores primários adicionais, correlacionando com o método realizado para elucidação do diagnóstico e relatórios anatomopatológicos. Materiais e Métodos: Avaliamos, retrospectivamente, prontuários, relatórios anatomopatológicos e exames de 11 pacientes que realizaram 18F-FDG PET/TC e/ou TC. Foram incluídos pacientes que apresentaram pelo menos duas neoplasias, com histopatologia distinta confirmada nos diferentes locais. Foram excluídos pacientes sem confirmação diagnóstica e pacientes com suspeita de que a lesão adicional fosse uma metástase da primeira. Resultados: Lesões sugestivas de novas malignidades primárias foram encontradas em 11 pacientes, apresentando em 10 deles uma única nova lesão e em 1 caso dois novos tumores. Locais comprovados de lesão adicional foram pulmão, rim, próstata, jejuno e mama. Biópsia percutânea única ou múltipla foi realizada em 10 pacientes e 1 paciente foi submetido a procedimento cirúrgico para fins diagnósticos e terapêuticos. Os tumores eram metacrônicos em 6 casos e sincrônicos em 5 pacientes. Conclusão: A TC e a 18F-FDG PET/TC associadas a biópsias percutâneas múltiplas podem auxiliar no diagnóstico de lesões adicionais, otimizando o tratamento e acompanhamento desses pacientes.

3.
Braz. j. infect. dis ; 14(5): 540-543, Sept.-Oct. 2010. ilus
Article in English | LILACS | ID: lil-570573

ABSTRACT

Paracoccidioidomycosis (PCM) or South American Blastomycosis is a systemic fungal infection caused by a dimorphic fungus, Paracoccidioides brasiliensis. It represents the most important systemic mycosis in South America and with higher prevalence among male inhabitants of the rural area. PCM usually affects the lungs, and rarely the intestines. The authors report three cases of PCM, treated at the University Hospital of Universidade Federal de Mato Grosso do Sul whose scintigraphy with technetium-99 labeled human albumin revead intestinal protein loss.


Subject(s)
Adult , Humans , Male , Paracoccidioides/isolation & purification , Paracoccidioidomycosis , Protein-Losing Enteropathies , Anti-Infective Agents/therapeutic use , Itraconazole/therapeutic use , Paracoccidioidomycosis/complications , Paracoccidioidomycosis/drug therapy , Protein-Losing Enteropathies/drug therapy , Protein-Losing Enteropathies/microbiology , Trimethoprim, Sulfamethoxazole Drug Combination/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL